Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 6, 2024; 12(25): 5805-5813
Published online Sep 6, 2024. doi: 10.12998/wjcc.v12.i25.5805
Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report
Ming-Xing Wang, Pei Zhu, Yue Shi, Qing-Ming Sun, Wan-Hui Dong
Ming-Xing Wang, Pei Zhu, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Lu’an 237000, Anhui Province, China
Yue Shi, Qing-Ming Sun, Wan-Hui Dong, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, Lu’an 237000, Anhui Province, China
Author contributions: Wang MX, Zhu P, Shi Y, Sun QM, and Dong WH designed the research study; Wang MX and Dong WH performed the research; Zhu P, Shi Y, and Sun QM contributed new reagents and analytic tools; Wang MX and Dong WH analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wan-Hui Dong, MD, Chief Doctor, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, No. 76 Renmin Road, Lu’an 237000, Anhui Province, China. dongwanhui@laszyy.cn
Received: April 19, 2024
Revised: June 22, 2024
Accepted: June 28, 2024
Published online: September 6, 2024
Processing time: 89 Days and 2.1 Hours
Core Tip

Core Tip: In this study, we demonstrate the efficacy of sotorasib in treating advanced non-small cell lung cancer with the KRAS G12C mutation. A patient diagnosed with stage IVB adenocarcinoma, exhibiting pelvic and bone metastases, showed a significant improvement in clinical symptoms post-sotorasib treatment, with no severe side effects observed. This case highlights the potential of targeted therapies in personalized cancer treatment, emphasizing the importance of genomic profiling for therapeutic decision-making.